8-K: Arvinas and Pfizer Announce Pivotal Phase 3 Success for Vepdegestrant in ESR1-Mutant Breast Cancer

Arvinas, Inc. and Pfizer, Inc. have unveiled detailed positive results from the Phase 3 VERITAC-2 clinical trial, demonstrating vepdegestrant's significant improvement in progression-free survival for patients with ESR1-mutant, ER+/HER2advanced breast cancer.

Summary

• Detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with ER+/HER2advanced or metastatic breast cancer were announced.
• The trial focused on patients whose disease progressed following prior treatment with CDK4/6 inhibitors and endocrine therapy.
• Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among ESR1-mutant patients, reducing the risk of disease progression or death by 43% compared to fulvestrant [Hazard Ratio (HR)=0.57 (95% CI 0.42-0.77); 2-sided P<0.001].
• The median PFS, as assessed by blinded independent central review (BICR), was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant in ESR1-mutant patients.
• The trial did not reach statistical significance in improvement in PFS in the overall intent-to-treat (ITT) population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 months for fulvestrant [HR=0.83 (95% CI 0.68-1.02); 2-sided P=0.07].
• Vepdegestrant was generally well tolerated, with a safety profile consistent with previous studies and mostly low-grade treatment-emergent adverse events (TEAEs).
• Rates and severity of gastrointestinal adverse events were low with vepdegestrant (nausea, 13.5%; vomiting, 6.4%; diarrhea, 6.4%).
• Grade 4 TEAEs were reported in 1.6% of patients in the vepdegestrant arm versus 2.9% in the fulvestrant arm.
• The three most common TEAEs observed with vepdegestrant were fatigue (26.6%), increased alanine transaminase (ALT) (14.4%), and increased aspartate aminotransferase (AST) (14.4%).
• TEAEs leading to treatment discontinuation occurred in 2.9% of patients taking vepdegestrant versus 0.7% of patients taking fulvestrant.
• Overall survival (OS) data was immature at the time of analysis.
• In ESR1-mutant patients, clinical benefit rate (CBR) was 42.1% with vepdegestrant versus 20.2% with fulvestrant [odds ratio 2.88; nominal P<0.001], and objective response rate (ORR) was 18.6% with vepdegestrant versus 4.0% with fulvestrant [odds ratio 5.45; nominal P=0.001].
• The median duration of response was not reached for ESR1-mutant patients.

Sentiment

Score: 9

Explanation: The detailed Phase 3 results for vepdegestrant are highly positive, demonstrating statistically significant and clinically meaningful improvements in progression-free survival for a critical subset of breast cancer patients (ESR1-mutant) who have limited treatment options. The favorable safety profile, 'best-in-class' potential, and clear regulatory path with a planned NDA submission contribute to a very strong positive sentiment.

Positives

• Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for ESR1-mutant patients, reducing the risk of disease progression or death by 43% compared to fulvestrant.
• The median PFS for ESR1-mutant patients was 5.0 months with vepdegestrant, significantly longer than 2.1 months with fulvestrant.
• Vepdegestrant was generally well tolerated with a favorable safety profile, showing mostly low-grade treatment-emergent adverse events (TEAEs) and low rates of gastrointestinal side effects.
• Lower incidence of Grade 4 TEAEs (1.6%) in the vepdegestrant arm compared to the fulvestrant arm (2.9%).
• Significant improvements were observed in clinical benefit rate (CBR) and objective response rate (ORR) for ESR1-mutant patients.
• The detailed results were highlighted in the American Society of Clinical Oncology (ASCO) press briefing and selected for 'Best of ASCO', indicating high scientific recognition.
• The data was presented in a late-breaking oral presentation and simultaneously published in the prestigious New England Journal of Medicine.
• Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer, highlighting its innovative mechanism.
• The company believes vepdegestrant has the potential to be a 'best-in-class' monotherapy treatment for patients in the second-line ESR1-mutant setting.

Negatives

• The trial did not reach statistical significance in improvement in progression-free survival (PFS) in the overall intent-to-treat (ITT) population (median PFS 3.7 months for vepdegestrant vs. 3.6 months for fulvestrant; P=0.07).
• Treatment-emergent adverse events (TEAEs) leading to treatment discontinuation were higher in the vepdegestrant arm (2.9%) compared to the fulvestrant arm (0.7%).
• Overall survival (OS), a key secondary endpoint, was immature at the time of the analysis, with less than a quarter of the required number of events having occurred.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from plans.
• There is uncertainty regarding whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration.
• Uncertainty exists regarding the successful conduct and completion of clinical development for vepdegestrant and other product candidates.
• There is a risk that the VERITAC-2 clinical trial may not meet the secondary endpoint for overall survival.
• Regulatory authorities may not be satisfied with the design or results from clinical studies, potentially impacting approval.
• There is no guarantee that drug applications will be filed or approved in any jurisdictions, or that vepdegestrant will be commercially successful if approved.
• Decisions by regulatory authorities could impact labeling, manufacturing processes, safety, and/or commercial potential of vepdegestrant.
• The company's ability to protect its intellectual property portfolio is a risk.
• Reliance on third parties for various aspects of development and commercialization poses a risk.
• There is a risk regarding the company's ability to raise capital when needed.
• The sufficiency of cash and cash equivalents to fund foreseeable and unforeseeable operating expenses and capital expenditure requirements is a risk.
• Risks and uncertainties related to future executive orders or changes in laws or regulations could impact operations.
• Uncertainties regarding the impact of COVID-19 on business, operations, and financial results are noted.
• Competitive developments in the breast cancer treatment landscape could affect vepdegestrant's market position.

Future Outlook

Arvinas and Pfizer plan to engage with regulatory authorities on next steps to potentially bring vepdegestrant to healthcare providers and their patients. They intend to submit a New Drug Application (NDA) for vepdegestrant to the U.S. Food & Drug Administration (FDA) in the second half of 2025. The company believes that based on these strong data, vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1-mutant setting.

Management Comments

• Erika P. Hamilton, M.D., Director, Breast Cancer Research, Sarah Cannon Research Institute, and a principal investigator of the VERITAC-2 trial, stated: 'The VERITAC-2 results are promising and suggest that vepdegestrant could offer a much-needed treatment option for these patients, with a low incidence of burdensome GI effects that can meaningfully affect daily life.'
• John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas, commented: 'Based on these strong data from VERITAC-2, we believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for patients in the second-line ESR1-mutant setting. We are excited to engage with regulatory authorities on next steps to potentially bring vepdegestrant to healthcare providers and their patients as swiftly as possible.'
• Johanna Bendell, M.D., Chief Oncology Development Officer, Pfizer, remarked: 'These results highlight the important role vepdegestrant may play in combating ESR1 mutation treatment resistance for these patients.'

Industry Context

Breast cancer remains a significant global health challenge, with approximately 2.3 million new diagnoses reported globally in 2022 and an estimated 320,000 new diagnoses in the United States in 2025. ER+/HER2breast cancer constitutes about 70% of all cases. A substantial portion of patients (nearly 30%) initially diagnosed with early-stage breast cancer will eventually develop metastatic disease, often facing resistance to current standard-of-care treatments. ESR1 mutations are a common cause of acquired resistance, found in approximately 40% of patients in the second-line setting, leading to poor prognosis and rapid disease progression. Vepdegestrant, as an investigational oral PROTAC ER degrader, represents a novel approach designed to specifically target and degrade the estrogen receptor, addressing a critical unmet need in this resistant patient population.

Comparison to Industry Standards

• Vepdegestrant was directly compared to fulvestrant, a current standard endocrine therapy, in the Phase 3 VERITAC-2 clinical trial.
• In ESR1-mutant patients, vepdegestrant demonstrated a superior median progression-free survival (PFS) of 5.0 months compared to 2.1 months for fulvestrant.
• Vepdegestrant showed significantly higher clinical benefit rate (CBR) of 42.1% versus 20.2% for fulvestrant in ESR1-mutant patients.
• The objective response rate (ORR) for vepdegestrant was 18.6% compared to 4.0% for fulvestrant in ESR1-mutant patients.
• Vepdegestrant is highlighted as the 'first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer,' positioning it as a pioneering therapy within the PROTAC class.
• The document references other trials and drugs such as Elacestrant (EMERALD Trial), Abemaciclib (postMONARCH Trial), and Amcenestrant (AMEERA-3) in the context of ESR1 mutations and advanced breast cancer, suggesting vepdegestrant's results are competitive or potentially superior in addressing this specific resistance mechanism.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical trial results, which significantly de-risk the drug's development and enhance its market potential, potentially leading to increased company valuation and future revenue streams.
• Patients (ER+/HER2advanced/metastatic breast cancer with ESR1 mutations): Significant positive impact as vepdegestrant offers a much-needed, effective, and well-tolerated oral treatment option for a patient population that often experiences resistance to standard therapies and faces a poor prognosis.
• Healthcare Providers: Provides a new, potentially superior, oral monotherapy option for treating a challenging and growing subset of breast cancer patients.
• Pfizer: Positive impact on its oncology pipeline and market position through the co-development and co-commercialization agreement, reinforcing its commitment to innovative cancer therapies.

Next Steps

• Arvinas and Pfizer plan to engage with regulatory authorities on next steps to potentially bring vepdegestrant to healthcare providers and their patients.
• The companies plan to submit a New Drug Application (NDA) for vepdegestrant to the U.S. Food & Drug Administration (FDA) in the second half of 2025.
• Arvinas will host a conference call and webcast on June 2, 2025, to review the detailed data from the VERITAC-2 trial.

Key Dates

Recommendation

Keywords

Vepdegestrant, ARV-471, PROTAC, Estrogen Receptor Degrader, ER+/HER2Breast Cancer, Metastatic Breast Cancer, ESR1 Mutation, Phase 3 Clinical Trial, VERITAC-2, Progression-Free Survival, Oncology, Drug Development, FDA NDA Submission, Arvinas, Pfizer